Does Jardiance Cause Ketoacidosis?
Jardiance (empagliflozin), an SGLT2 inhibitor for type 2 diabetes, carries a risk of ketoacidosis, including euglycemic diabetic ketoacidosis (DKA) where blood sugar stays normal or only mildly elevated. The FDA added a boxed warning to its label in 2016 after post-marketing reports confirmed cases, often in patients with type 1 diabetes (off-label use), surgery, dehydration, or low-carb diets. Incidence is low—about 0.1-0.7 cases per 1,000 patient-years in trials—but symptoms like nausea, vomiting, abdominal pain, fatigue, and rapid breathing can mimic other issues, delaying diagnosis.[1][2]
How Does Jardiance Trigger Ketoacidosis?
It blocks glucose reabsorption in kidneys, lowering blood sugar and insulin demand. This shifts the body to fat breakdown, producing ketones. In susceptible patients, factors like illness, fasting, alcohol, or pancreatitis amplify this, leading to acidosis even without hyperglycemia.[1][3]
Who Is Most at Risk?
Highest risk in type 1 diabetes users (contraindicated), those with history of DKA, renal impairment, or on ketogenic diets. Type 2 patients face lower risk but should monitor during acute illness or procedures. Pancreatitis or gallbladder issues increase odds.[2][4]
What Symptoms Should You Watch For?
Nausea, vomiting, stomach pain, tiredness, fruity breath, confusion, or trouble breathing. Test urine/blood ketones if blood sugar is under 250 mg/dL but symptoms appear. Stop Jardiance and seek care immediately.[1][3]
How Is It Diagnosed and Treated?
Blood tests show high ketones, low bicarbonate, anion gap acidosis. Treatment involves IV fluids, insulin, electrolytes, and stopping SGLT2 inhibitors. Hospitalization is common; recovery takes days.[2]
Can It Happen Without High Blood Sugar?
Yes, euglycemic DKA is a hallmark—glucose often 100-200 mg/dL. This tricked early detection, prompting the FDA warning.[1][4]
Prevention Tips for Patients
Check ketones during illness, surgery, or diet changes. Stay hydrated, eat carbs if sick, and inform doctors pre-procedure. FDA advises holding the drug 3-4 days before surgery.[3]
Comparison to Other SGLT2 Inhibitors
Invokana, Farxiga, and Steglatro share the same boxed warning and similar risks (0.1-1 case per 1,000 patient-years). No major differences in trial data.[1][2]
[1]: FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes
[2]: Jardiance Prescribing Information
[3]: American Diabetes Association Standards of Care 2023
[4]: NEJM: SGLT2 Inhibitors and Ketoacidosis